nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—MTOR—obesity	0.52	1	CbGaD
Everolimus—CYP3A4—Sibutramine—obesity	0.0434	0.27	CbGbCtD
Everolimus—CYP3A4—Benzphetamine—obesity	0.0329	0.204	CbGbCtD
Everolimus—CYP3A4—Bupropion—obesity	0.028	0.174	CbGbCtD
Everolimus—CYP3A4—Orlistat—obesity	0.0228	0.142	CbGbCtD
Everolimus—CYP3A4—Cimetidine—obesity	0.0205	0.127	CbGbCtD
Everolimus—CYP3A4—Topiramate—obesity	0.0134	0.0834	CbGbCtD
Everolimus—MTOR—hindbrain—obesity	0.00336	0.125	CbGeAlD
Everolimus—MTOR—respiratory system—obesity	0.00205	0.0766	CbGeAlD
Everolimus—FKBP1A—respiratory system—obesity	0.00185	0.0689	CbGeAlD
Everolimus—MTOR—cardiovascular system—obesity	0.00157	0.0587	CbGeAlD
Everolimus—Pimecrolimus—MTOR—obesity	0.00157	0.336	CrCbGaD
Everolimus—FKBP1A—adrenal cortex—obesity	0.00155	0.0578	CbGeAlD
Everolimus—FKBP1A—cardiovascular system—obesity	0.00141	0.0528	CbGeAlD
Everolimus—MTOR—pituitary gland—obesity	0.00139	0.0519	CbGeAlD
Everolimus—MTOR—adipose tissue—obesity	0.00139	0.0517	CbGeAlD
Everolimus—MTOR—digestive system—obesity	0.00131	0.0487	CbGeAlD
Everolimus—FKBP1A—pituitary gland—obesity	0.00125	0.0467	CbGeAlD
Everolimus—FKBP1A—adipose tissue—obesity	0.00125	0.0465	CbGeAlD
Everolimus—MTOR—adrenal gland—obesity	0.00124	0.0464	CbGeAlD
Everolimus—FKBP1A—digestive system—obesity	0.00117	0.0438	CbGeAlD
Everolimus—FKBP1A—adrenal gland—obesity	0.00112	0.0417	CbGeAlD
Everolimus—MTOR—endocrine gland—obesity	0.00108	0.0402	CbGeAlD
Everolimus—Temsirolimus—MTOR—obesity	0.00106	0.227	CrCbGaD
Everolimus—MTOR—liver—obesity	0.000973	0.0363	CbGeAlD
Everolimus—FKBP1A—endocrine gland—obesity	0.00097	0.0362	CbGeAlD
Everolimus—Tacrolimus—MTOR—obesity	0.000931	0.2	CrCbGaD
Everolimus—Sirolimus—MTOR—obesity	0.000931	0.2	CrCbGaD
Everolimus—FKBP1A—liver—obesity	0.000875	0.0326	CbGeAlD
Everolimus—CYP3A4—digestive system—obesity	0.000384	0.0143	CbGeAlD
Everolimus—CYP3A4—endocrine gland—obesity	0.000317	0.0118	CbGeAlD
Everolimus—CYP3A4—liver—obesity	0.000286	0.0107	CbGeAlD
Everolimus—Tacrolimus—ALB—obesity	0.000168	0.036	CrCbGaD
Everolimus—Urinary retention—Topiramate—obesity	0.000108	0.000624	CcSEcCtD
Everolimus—Anxiety—Orlistat—obesity	0.000108	0.000624	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Orlistat—obesity	0.000108	0.000622	CcSEcCtD
Everolimus—Cough—Sibutramine—obesity	0.000107	0.000621	CcSEcCtD
Everolimus—Malnutrition—Bupropion—obesity	0.000107	0.00062	CcSEcCtD
Everolimus—Discomfort—Orlistat—obesity	0.000107	0.000618	CcSEcCtD
Everolimus—Convulsion—Sibutramine—obesity	0.000107	0.000617	CcSEcCtD
Everolimus—Blood creatinine increased—Topiramate—obesity	0.000106	0.000615	CcSEcCtD
Everolimus—Hypertension—Sibutramine—obesity	0.000106	0.000614	CcSEcCtD
Everolimus—Dry mouth—Orlistat—obesity	0.000106	0.000612	CcSEcCtD
Everolimus—Flatulence—Bupropion—obesity	0.000106	0.000611	CcSEcCtD
Everolimus—Dehydration—Topiramate—obesity	0.000106	0.00061	CcSEcCtD
Everolimus—Dysgeusia—Bupropion—obesity	0.000105	0.000607	CcSEcCtD
Everolimus—Liver function test abnormal—Topiramate—obesity	0.000105	0.000606	CcSEcCtD
Everolimus—Chest pain—Sibutramine—obesity	0.000105	0.000606	CcSEcCtD
Everolimus—Arthralgia—Sibutramine—obesity	0.000105	0.000606	CcSEcCtD
Everolimus—Myalgia—Sibutramine—obesity	0.000105	0.000606	CcSEcCtD
Everolimus—Anxiety—Sibutramine—obesity	0.000104	0.000604	CcSEcCtD
Everolimus—Oedema—Orlistat—obesity	0.000104	0.0006	CcSEcCtD
Everolimus—Back pain—Bupropion—obesity	0.000104	0.0006	CcSEcCtD
Everolimus—Abdominal pain upper—Topiramate—obesity	0.000104	0.000599	CcSEcCtD
Everolimus—Discomfort—Sibutramine—obesity	0.000104	0.000599	CcSEcCtD
Everolimus—Hypokalaemia—Topiramate—obesity	0.000103	0.000597	CcSEcCtD
Everolimus—Muscle spasms—Bupropion—obesity	0.000103	0.000596	CcSEcCtD
Everolimus—Infection—Orlistat—obesity	0.000103	0.000596	CcSEcCtD
Everolimus—Breast disorder—Topiramate—obesity	0.000103	0.000593	CcSEcCtD
Everolimus—Dry mouth—Sibutramine—obesity	0.000103	0.000592	CcSEcCtD
Everolimus—Aspartate aminotransferase increased—Topiramate—obesity	0.000102	0.000591	CcSEcCtD
Everolimus—Nervous system disorder—Orlistat—obesity	0.000102	0.000588	CcSEcCtD
Everolimus—Nasopharyngitis—Topiramate—obesity	0.000102	0.000587	CcSEcCtD
Everolimus—Vision blurred—Bupropion—obesity	0.000101	0.000585	CcSEcCtD
Everolimus—Skin disorder—Orlistat—obesity	0.000101	0.000583	CcSEcCtD
Everolimus—Tremor—Bupropion—obesity	0.000101	0.000581	CcSEcCtD
Everolimus—Gastritis—Topiramate—obesity	0.000101	0.000581	CcSEcCtD
Everolimus—Oedema—Sibutramine—obesity	0.0001	0.000581	CcSEcCtD
Everolimus—Hyperhidrosis—Orlistat—obesity	0.0001	0.00058	CcSEcCtD
Everolimus—Alanine aminotransferase increased—Topiramate—obesity	0.0001	0.000579	CcSEcCtD
Everolimus—Muscular weakness—Topiramate—obesity	0.0001	0.000579	CcSEcCtD
Everolimus—Infection—Sibutramine—obesity	9.98e-05	0.000577	CcSEcCtD
Everolimus—Ill-defined disorder—Bupropion—obesity	9.96e-05	0.000576	CcSEcCtD
Everolimus—Anaemia—Bupropion—obesity	9.92e-05	0.000573	CcSEcCtD
Everolimus—Shock—Sibutramine—obesity	9.89e-05	0.000571	CcSEcCtD
Everolimus—Abdominal distension—Topiramate—obesity	9.88e-05	0.000571	CcSEcCtD
Everolimus—Agitation—Bupropion—obesity	9.87e-05	0.00057	CcSEcCtD
Everolimus—Thrombocytopenia—Sibutramine—obesity	9.84e-05	0.000569	CcSEcCtD
Everolimus—Dysphagia—Topiramate—obesity	9.82e-05	0.000567	CcSEcCtD
Everolimus—Angioedema—Bupropion—obesity	9.81e-05	0.000567	CcSEcCtD
Everolimus—Tachycardia—Sibutramine—obesity	9.81e-05	0.000567	CcSEcCtD
Everolimus—Skin disorder—Sibutramine—obesity	9.76e-05	0.000564	CcSEcCtD
Everolimus—Hyperhidrosis—Sibutramine—obesity	9.72e-05	0.000561	CcSEcCtD
Everolimus—Malaise—Bupropion—obesity	9.68e-05	0.000559	CcSEcCtD
Everolimus—Syncope—Bupropion—obesity	9.63e-05	0.000556	CcSEcCtD
Everolimus—Pancreatitis—Topiramate—obesity	9.62e-05	0.000556	CcSEcCtD
Everolimus—Leukopenia—Bupropion—obesity	9.61e-05	0.000555	CcSEcCtD
Everolimus—Anorexia—Sibutramine—obesity	9.58e-05	0.000554	CcSEcCtD
Everolimus—Angina pectoris—Topiramate—obesity	9.56e-05	0.000553	CcSEcCtD
Everolimus—Palpitations—Bupropion—obesity	9.49e-05	0.000548	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Orlistat—obesity	9.46e-05	0.000547	CcSEcCtD
Everolimus—Bronchitis—Topiramate—obesity	9.44e-05	0.000546	CcSEcCtD
Everolimus—Loss of consciousness—Bupropion—obesity	9.44e-05	0.000545	CcSEcCtD
Everolimus—Insomnia—Orlistat—obesity	9.39e-05	0.000543	CcSEcCtD
Everolimus—Hypotension—Sibutramine—obesity	9.39e-05	0.000543	CcSEcCtD
Everolimus—Cough—Bupropion—obesity	9.37e-05	0.000541	CcSEcCtD
Everolimus—Paraesthesia—Orlistat—obesity	9.32e-05	0.000539	CcSEcCtD
Everolimus—Pancytopenia—Topiramate—obesity	9.32e-05	0.000539	CcSEcCtD
Everolimus—Convulsion—Bupropion—obesity	9.3e-05	0.000537	CcSEcCtD
Everolimus—Hypertension—Bupropion—obesity	9.27e-05	0.000536	CcSEcCtD
Everolimus—Neutropenia—Topiramate—obesity	9.18e-05	0.00053	CcSEcCtD
Everolimus—Dysuria—Topiramate—obesity	9.18e-05	0.00053	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Sibutramine—obesity	9.16e-05	0.000529	CcSEcCtD
Everolimus—Dyspepsia—Orlistat—obesity	9.14e-05	0.000528	CcSEcCtD
Everolimus—Arthralgia—Bupropion—obesity	9.14e-05	0.000528	CcSEcCtD
Everolimus—Myalgia—Bupropion—obesity	9.14e-05	0.000528	CcSEcCtD
Everolimus—Chest pain—Bupropion—obesity	9.14e-05	0.000528	CcSEcCtD
Everolimus—Upper respiratory tract infection—Topiramate—obesity	9.12e-05	0.000527	CcSEcCtD
Everolimus—Anxiety—Bupropion—obesity	9.11e-05	0.000526	CcSEcCtD
Everolimus—Insomnia—Sibutramine—obesity	9.09e-05	0.000525	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Bupropion—obesity	9.08e-05	0.000525	CcSEcCtD
Everolimus—Pollakiuria—Topiramate—obesity	9.07e-05	0.000524	CcSEcCtD
Everolimus—Erectile dysfunction—Topiramate—obesity	9.04e-05	0.000522	CcSEcCtD
Everolimus—Discomfort—Bupropion—obesity	9.03e-05	0.000522	CcSEcCtD
Everolimus—Decreased appetite—Orlistat—obesity	9.03e-05	0.000522	CcSEcCtD
Everolimus—Paraesthesia—Sibutramine—obesity	9.02e-05	0.000521	CcSEcCtD
Everolimus—Gastrointestinal disorder—Orlistat—obesity	8.96e-05	0.000518	CcSEcCtD
Everolimus—Dyspnoea—Sibutramine—obesity	8.96e-05	0.000518	CcSEcCtD
Everolimus—Fatigue—Orlistat—obesity	8.95e-05	0.000517	CcSEcCtD
Everolimus—Dry mouth—Bupropion—obesity	8.94e-05	0.000517	CcSEcCtD
Everolimus—Somnolence—Sibutramine—obesity	8.93e-05	0.000516	CcSEcCtD
Everolimus—Weight decreased—Topiramate—obesity	8.88e-05	0.000513	CcSEcCtD
Everolimus—Pain—Orlistat—obesity	8.88e-05	0.000513	CcSEcCtD
Everolimus—Hyperglycaemia—Topiramate—obesity	8.85e-05	0.000512	CcSEcCtD
Everolimus—Dyspepsia—Sibutramine—obesity	8.85e-05	0.000511	CcSEcCtD
Everolimus—Pneumonia—Topiramate—obesity	8.8e-05	0.000509	CcSEcCtD
Everolimus—Oedema—Bupropion—obesity	8.76e-05	0.000506	CcSEcCtD
Everolimus—Infestation NOS—Topiramate—obesity	8.75e-05	0.000506	CcSEcCtD
Everolimus—Infestation—Topiramate—obesity	8.75e-05	0.000506	CcSEcCtD
Everolimus—Decreased appetite—Sibutramine—obesity	8.74e-05	0.000505	CcSEcCtD
Everolimus—Infection—Bupropion—obesity	8.7e-05	0.000503	CcSEcCtD
Everolimus—Gastrointestinal disorder—Sibutramine—obesity	8.68e-05	0.000501	CcSEcCtD
Everolimus—Shock—Bupropion—obesity	8.62e-05	0.000498	CcSEcCtD
Everolimus—Renal failure—Topiramate—obesity	8.6e-05	0.000497	CcSEcCtD
Everolimus—Constipation—Sibutramine—obesity	8.59e-05	0.000497	CcSEcCtD
Everolimus—Pain—Sibutramine—obesity	8.59e-05	0.000497	CcSEcCtD
Everolimus—Nervous system disorder—Bupropion—obesity	8.59e-05	0.000497	CcSEcCtD
Everolimus—Thrombocytopenia—Bupropion—obesity	8.58e-05	0.000496	CcSEcCtD
Everolimus—Feeling abnormal—Orlistat—obesity	8.56e-05	0.000495	CcSEcCtD
Everolimus—Tachycardia—Bupropion—obesity	8.55e-05	0.000494	CcSEcCtD
Everolimus—Stomatitis—Topiramate—obesity	8.53e-05	0.000493	CcSEcCtD
Everolimus—Skin disorder—Bupropion—obesity	8.51e-05	0.000492	CcSEcCtD
Everolimus—Conjunctivitis—Topiramate—obesity	8.51e-05	0.000492	CcSEcCtD
Everolimus—Urinary tract infection—Topiramate—obesity	8.51e-05	0.000492	CcSEcCtD
Everolimus—Gastrointestinal pain—Orlistat—obesity	8.49e-05	0.000491	CcSEcCtD
Everolimus—Hyperhidrosis—Bupropion—obesity	8.47e-05	0.000489	CcSEcCtD
Everolimus—Anorexia—Bupropion—obesity	8.35e-05	0.000483	CcSEcCtD
Everolimus—Haematuria—Topiramate—obesity	8.34e-05	0.000482	CcSEcCtD
Everolimus—Feeling abnormal—Sibutramine—obesity	8.28e-05	0.000479	CcSEcCtD
Everolimus—Epistaxis—Topiramate—obesity	8.25e-05	0.000477	CcSEcCtD
Everolimus—Gastrointestinal pain—Sibutramine—obesity	8.22e-05	0.000475	CcSEcCtD
Everolimus—Sinusitis—Topiramate—obesity	8.21e-05	0.000474	CcSEcCtD
Everolimus—Abdominal pain—Orlistat—obesity	8.21e-05	0.000474	CcSEcCtD
Everolimus—Body temperature increased—Orlistat—obesity	8.21e-05	0.000474	CcSEcCtD
Everolimus—Hypotension—Bupropion—obesity	8.19e-05	0.000473	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Bupropion—obesity	7.98e-05	0.000461	CcSEcCtD
Everolimus—Abdominal pain—Sibutramine—obesity	7.94e-05	0.000459	CcSEcCtD
Everolimus—Body temperature increased—Sibutramine—obesity	7.94e-05	0.000459	CcSEcCtD
Everolimus—Insomnia—Bupropion—obesity	7.92e-05	0.000458	CcSEcCtD
Everolimus—Haemoglobin—Topiramate—obesity	7.9e-05	0.000456	CcSEcCtD
Everolimus—Rhinitis—Topiramate—obesity	7.88e-05	0.000455	CcSEcCtD
Everolimus—Paraesthesia—Bupropion—obesity	7.87e-05	0.000455	CcSEcCtD
Everolimus—Haemorrhage—Topiramate—obesity	7.86e-05	0.000454	CcSEcCtD
Everolimus—Hepatitis—Topiramate—obesity	7.86e-05	0.000454	CcSEcCtD
Everolimus—Hypoaesthesia—Topiramate—obesity	7.82e-05	0.000452	CcSEcCtD
Everolimus—Hallucination—Topiramate—obesity	7.82e-05	0.000452	CcSEcCtD
Everolimus—Dyspnoea—Bupropion—obesity	7.81e-05	0.000451	CcSEcCtD
Everolimus—Pharyngitis—Topiramate—obesity	7.8e-05	0.000451	CcSEcCtD
Everolimus—Somnolence—Bupropion—obesity	7.79e-05	0.00045	CcSEcCtD
Everolimus—Urinary tract disorder—Topiramate—obesity	7.76e-05	0.000448	CcSEcCtD
Everolimus—Oedema peripheral—Topiramate—obesity	7.74e-05	0.000447	CcSEcCtD
Everolimus—Connective tissue disorder—Topiramate—obesity	7.72e-05	0.000446	CcSEcCtD
Everolimus—Dyspepsia—Bupropion—obesity	7.71e-05	0.000446	CcSEcCtD
Everolimus—Urethral disorder—Topiramate—obesity	7.7e-05	0.000445	CcSEcCtD
Everolimus—Hypersensitivity—Orlistat—obesity	7.65e-05	0.000442	CcSEcCtD
Everolimus—Decreased appetite—Bupropion—obesity	7.62e-05	0.00044	CcSEcCtD
Everolimus—Gastrointestinal disorder—Bupropion—obesity	7.56e-05	0.000437	CcSEcCtD
Everolimus—Fatigue—Bupropion—obesity	7.55e-05	0.000437	CcSEcCtD
Everolimus—Pain—Bupropion—obesity	7.49e-05	0.000433	CcSEcCtD
Everolimus—Constipation—Bupropion—obesity	7.49e-05	0.000433	CcSEcCtD
Everolimus—Asthenia—Orlistat—obesity	7.45e-05	0.000431	CcSEcCtD
Everolimus—Hypersensitivity—Sibutramine—obesity	7.4e-05	0.000428	CcSEcCtD
Everolimus—Pruritus—Orlistat—obesity	7.35e-05	0.000425	CcSEcCtD
Everolimus—Eye disorder—Topiramate—obesity	7.34e-05	0.000424	CcSEcCtD
Everolimus—Cardiac disorder—Topiramate—obesity	7.29e-05	0.000421	CcSEcCtD
Everolimus—Flushing—Topiramate—obesity	7.29e-05	0.000421	CcSEcCtD
Everolimus—Feeling abnormal—Bupropion—obesity	7.22e-05	0.000417	CcSEcCtD
Everolimus—Asthenia—Sibutramine—obesity	7.21e-05	0.000417	CcSEcCtD
Everolimus—Gastrointestinal pain—Bupropion—obesity	7.16e-05	0.000414	CcSEcCtD
Everolimus—Angiopathy—Topiramate—obesity	7.13e-05	0.000412	CcSEcCtD
Everolimus—Pruritus—Sibutramine—obesity	7.11e-05	0.000411	CcSEcCtD
Everolimus—Diarrhoea—Orlistat—obesity	7.1e-05	0.000411	CcSEcCtD
Everolimus—Immune system disorder—Topiramate—obesity	7.1e-05	0.00041	CcSEcCtD
Everolimus—Mediastinal disorder—Topiramate—obesity	7.08e-05	0.000409	CcSEcCtD
Everolimus—Chills—Topiramate—obesity	7.05e-05	0.000407	CcSEcCtD
Everolimus—Alopecia—Topiramate—obesity	6.94e-05	0.000401	CcSEcCtD
Everolimus—Body temperature increased—Bupropion—obesity	6.93e-05	0.0004	CcSEcCtD
Everolimus—Abdominal pain—Bupropion—obesity	6.93e-05	0.0004	CcSEcCtD
Everolimus—Mental disorder—Topiramate—obesity	6.88e-05	0.000398	CcSEcCtD
Everolimus—Diarrhoea—Sibutramine—obesity	6.88e-05	0.000397	CcSEcCtD
Everolimus—Dizziness—Orlistat—obesity	6.87e-05	0.000397	CcSEcCtD
Everolimus—Malnutrition—Topiramate—obesity	6.84e-05	0.000395	CcSEcCtD
Everolimus—Erythema—Topiramate—obesity	6.84e-05	0.000395	CcSEcCtD
Everolimus—Flatulence—Topiramate—obesity	6.74e-05	0.000389	CcSEcCtD
Everolimus—Dysgeusia—Topiramate—obesity	6.7e-05	0.000387	CcSEcCtD
Everolimus—Dizziness—Sibutramine—obesity	6.65e-05	0.000384	CcSEcCtD
Everolimus—Back pain—Topiramate—obesity	6.62e-05	0.000382	CcSEcCtD
Everolimus—Vomiting—Orlistat—obesity	6.6e-05	0.000382	CcSEcCtD
Everolimus—Muscle spasms—Topiramate—obesity	6.58e-05	0.00038	CcSEcCtD
Everolimus—Rash—Orlistat—obesity	6.55e-05	0.000378	CcSEcCtD
Everolimus—Dermatitis—Orlistat—obesity	6.54e-05	0.000378	CcSEcCtD
Everolimus—Headache—Orlistat—obesity	6.51e-05	0.000376	CcSEcCtD
Everolimus—Hypersensitivity—Bupropion—obesity	6.45e-05	0.000373	CcSEcCtD
Everolimus—Vision blurred—Topiramate—obesity	6.45e-05	0.000372	CcSEcCtD
Everolimus—Tremor—Topiramate—obesity	6.41e-05	0.00037	CcSEcCtD
Everolimus—Vomiting—Sibutramine—obesity	6.39e-05	0.000369	CcSEcCtD
Everolimus—Ill-defined disorder—Topiramate—obesity	6.35e-05	0.000367	CcSEcCtD
Everolimus—Rash—Sibutramine—obesity	6.34e-05	0.000366	CcSEcCtD
Everolimus—Dermatitis—Sibutramine—obesity	6.33e-05	0.000366	CcSEcCtD
Everolimus—Anaemia—Topiramate—obesity	6.32e-05	0.000365	CcSEcCtD
Everolimus—Headache—Sibutramine—obesity	6.3e-05	0.000364	CcSEcCtD
Everolimus—Asthenia—Bupropion—obesity	6.29e-05	0.000363	CcSEcCtD
Everolimus—Agitation—Topiramate—obesity	6.29e-05	0.000363	CcSEcCtD
Everolimus—Pruritus—Bupropion—obesity	6.2e-05	0.000358	CcSEcCtD
Everolimus—Nausea—Orlistat—obesity	6.17e-05	0.000356	CcSEcCtD
Everolimus—Malaise—Topiramate—obesity	6.17e-05	0.000356	CcSEcCtD
Everolimus—Syncope—Topiramate—obesity	6.13e-05	0.000354	CcSEcCtD
Everolimus—Leukopenia—Topiramate—obesity	6.12e-05	0.000354	CcSEcCtD
Everolimus—Palpitations—Topiramate—obesity	6.04e-05	0.000349	CcSEcCtD
Everolimus—Loss of consciousness—Topiramate—obesity	6.01e-05	0.000347	CcSEcCtD
Everolimus—Diarrhoea—Bupropion—obesity	5.99e-05	0.000346	CcSEcCtD
Everolimus—Nausea—Sibutramine—obesity	5.97e-05	0.000345	CcSEcCtD
Everolimus—Cough—Topiramate—obesity	5.97e-05	0.000345	CcSEcCtD
Everolimus—Convulsion—Topiramate—obesity	5.93e-05	0.000342	CcSEcCtD
Everolimus—Hypertension—Topiramate—obesity	5.9e-05	0.000341	CcSEcCtD
Everolimus—Arthralgia—Topiramate—obesity	5.82e-05	0.000336	CcSEcCtD
Everolimus—Myalgia—Topiramate—obesity	5.82e-05	0.000336	CcSEcCtD
Everolimus—Chest pain—Topiramate—obesity	5.82e-05	0.000336	CcSEcCtD
Everolimus—Anxiety—Topiramate—obesity	5.8e-05	0.000335	CcSEcCtD
Everolimus—Dizziness—Bupropion—obesity	5.79e-05	0.000335	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Topiramate—obesity	5.78e-05	0.000334	CcSEcCtD
Everolimus—Discomfort—Topiramate—obesity	5.75e-05	0.000332	CcSEcCtD
Everolimus—Dry mouth—Topiramate—obesity	5.69e-05	0.000329	CcSEcCtD
Everolimus—Oedema—Topiramate—obesity	5.58e-05	0.000323	CcSEcCtD
Everolimus—Vomiting—Bupropion—obesity	5.57e-05	0.000322	CcSEcCtD
Everolimus—Infection—Topiramate—obesity	5.55e-05	0.00032	CcSEcCtD
Everolimus—Rash—Bupropion—obesity	5.52e-05	0.000319	CcSEcCtD
Everolimus—Dermatitis—Bupropion—obesity	5.52e-05	0.000319	CcSEcCtD
Everolimus—Shock—Topiramate—obesity	5.49e-05	0.000317	CcSEcCtD
Everolimus—Headache—Bupropion—obesity	5.49e-05	0.000317	CcSEcCtD
Everolimus—Nervous system disorder—Topiramate—obesity	5.47e-05	0.000316	CcSEcCtD
Everolimus—Thrombocytopenia—Topiramate—obesity	5.47e-05	0.000316	CcSEcCtD
Everolimus—Tachycardia—Topiramate—obesity	5.45e-05	0.000315	CcSEcCtD
Everolimus—Skin disorder—Topiramate—obesity	5.42e-05	0.000313	CcSEcCtD
Everolimus—Hyperhidrosis—Topiramate—obesity	5.4e-05	0.000312	CcSEcCtD
Everolimus—Anorexia—Topiramate—obesity	5.32e-05	0.000307	CcSEcCtD
Everolimus—Hypotension—Topiramate—obesity	5.22e-05	0.000301	CcSEcCtD
Everolimus—Nausea—Bupropion—obesity	5.2e-05	0.000301	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Topiramate—obesity	5.09e-05	0.000294	CcSEcCtD
Everolimus—Insomnia—Topiramate—obesity	5.05e-05	0.000292	CcSEcCtD
Everolimus—Paraesthesia—Topiramate—obesity	5.01e-05	0.00029	CcSEcCtD
Everolimus—Dyspnoea—Topiramate—obesity	4.98e-05	0.000288	CcSEcCtD
Everolimus—Somnolence—Topiramate—obesity	4.96e-05	0.000287	CcSEcCtD
Everolimus—Dyspepsia—Topiramate—obesity	4.91e-05	0.000284	CcSEcCtD
Everolimus—Decreased appetite—Topiramate—obesity	4.85e-05	0.00028	CcSEcCtD
Everolimus—Gastrointestinal disorder—Topiramate—obesity	4.82e-05	0.000278	CcSEcCtD
Everolimus—Fatigue—Topiramate—obesity	4.81e-05	0.000278	CcSEcCtD
Everolimus—Pain—Topiramate—obesity	4.77e-05	0.000276	CcSEcCtD
Everolimus—Constipation—Topiramate—obesity	4.77e-05	0.000276	CcSEcCtD
Everolimus—Feeling abnormal—Topiramate—obesity	4.6e-05	0.000266	CcSEcCtD
Everolimus—Gastrointestinal pain—Topiramate—obesity	4.56e-05	0.000264	CcSEcCtD
Everolimus—Abdominal pain—Topiramate—obesity	4.41e-05	0.000255	CcSEcCtD
Everolimus—Body temperature increased—Topiramate—obesity	4.41e-05	0.000255	CcSEcCtD
Everolimus—Hypersensitivity—Topiramate—obesity	4.11e-05	0.000238	CcSEcCtD
Everolimus—Asthenia—Topiramate—obesity	4e-05	0.000231	CcSEcCtD
Everolimus—Pruritus—Topiramate—obesity	3.95e-05	0.000228	CcSEcCtD
Everolimus—Diarrhoea—Topiramate—obesity	3.82e-05	0.000221	CcSEcCtD
Everolimus—Dizziness—Topiramate—obesity	3.69e-05	0.000213	CcSEcCtD
Everolimus—Vomiting—Topiramate—obesity	3.55e-05	0.000205	CcSEcCtD
Everolimus—Rash—Topiramate—obesity	3.52e-05	0.000203	CcSEcCtD
Everolimus—Dermatitis—Topiramate—obesity	3.52e-05	0.000203	CcSEcCtD
Everolimus—Headache—Topiramate—obesity	3.5e-05	0.000202	CcSEcCtD
Everolimus—Nausea—Topiramate—obesity	3.32e-05	0.000192	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—BAD—obesity	1.25e-05	0.000109	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—DRD4—obesity	1.25e-05	0.000109	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CG—obesity	1.21e-05	0.000106	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—AKT1—obesity	1.21e-05	0.000106	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SUCLG2—obesity	1.21e-05	0.000105	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ME1—obesity	1.21e-05	0.000105	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALDH6A1—obesity	1.21e-05	0.000105	CbGpPWpGaD
Everolimus—CYP3A4—Biological oxidations—POMC—obesity	1.21e-05	0.000105	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IRS1—obesity	1.2e-05	0.000105	CbGpPWpGaD
Everolimus—MTOR—Immune System—CRP—obesity	1.2e-05	0.000104	CbGpPWpGaD
Everolimus—MTOR—Immune System—IRS2—obesity	1.2e-05	0.000104	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CNR1—obesity	1.19e-05	0.000104	CbGpPWpGaD
Everolimus—MTOR—Disease—PRKCD—obesity	1.19e-05	0.000103	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—MAPK8—obesity	1.18e-05	0.000102	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TCF7L2—obesity	1.17e-05	0.000102	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—DRD2—obesity	1.16e-05	0.000101	CbGpPWpGaD
Everolimus—MTOR—Disease—MTHFR—obesity	1.16e-05	0.000101	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—POMC—obesity	1.16e-05	0.000101	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GCG—obesity	1.15e-05	0.0001	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTPN1—obesity	1.15e-05	0.0001	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—INS—obesity	1.15e-05	0.0001	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR4—obesity	1.15e-05	9.99e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PNPLA3—obesity	1.14e-05	9.91e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—COX7C—obesity	1.14e-05	9.91e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—UCP1—obesity	1.14e-05	9.91e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCL2—obesity	1.13e-05	9.85e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IGF1—obesity	1.11e-05	9.69e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT2—obesity	1.11e-05	9.68e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IRS2—obesity	1.1e-05	9.62e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PRKCB—obesity	1.1e-05	9.62e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—ICAM1—obesity	1.1e-05	9.58e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PRL—obesity	1.1e-05	9.56e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—BAD—obesity	1.09e-05	9.5e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STK11—obesity	1.08e-05	9.42e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—APOE—obesity	1.08e-05	9.42e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—DGAT2—obesity	1.08e-05	9.39e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CS—obesity	1.08e-05	9.39e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SUCLA2—obesity	1.08e-05	9.39e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CPS1—obesity	1.08e-05	9.39e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—CAV1—obesity	1.07e-05	9.33e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PLG—obesity	1.07e-05	9.32e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—APOA1—obesity	1.07e-05	9.31e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CD—obesity	1.07e-05	9.3e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SERPINE1—obesity	1.06e-05	9.2e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IRS1—obesity	1.04e-05	9.1e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FOXO3—obesity	1.04e-05	9.1e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADRB2—obesity	1.04e-05	9.07e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MUT—obesity	1.03e-05	8.96e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LIPE—obesity	1.03e-05	8.96e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TYK2—obesity	1.03e-05	8.95e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—STAT3—obesity	1.03e-05	8.95e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SOCS1—obesity	1.03e-05	8.93e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RHOA—obesity	1.02e-05	8.87e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SOCS3—obesity	1.01e-05	8.83e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3R1—obesity	1.01e-05	8.78e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOS3—obesity	1.01e-05	8.78e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—BAD—obesity	1.01e-05	8.77e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GNB3—obesity	9.92e-06	8.64e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYB5A—obesity	9.86e-06	8.59e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—DGAT1—obesity	9.86e-06	8.59e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF2—obesity	9.74e-06	8.49e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT2—obesity	9.67e-06	8.42e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GNAS—obesity	9.66e-06	8.41e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IRS1—obesity	9.64e-06	8.4e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MYC—obesity	9.54e-06	8.31e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TGFB1—obesity	9.52e-06	8.29e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ACLY—obesity	9.49e-06	8.27e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOB—obesity	9.46e-06	8.24e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MTOR—obesity	9.31e-06	8.11e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CB—obesity	9.31e-06	8.11e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CD—obesity	9.29e-06	8.09e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL5—obesity	9.24e-06	8.04e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—INS—obesity	9.23e-06	8.04e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALOX12—obesity	9.17e-06	7.99e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ENPP1—obesity	9.17e-06	7.99e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LPL—obesity	9.03e-06	7.87e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FOXO1—obesity	8.97e-06	7.81e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RPS6KB1—obesity	8.95e-06	7.8e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—TYK2—obesity	8.94e-06	7.78e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT2—obesity	8.93e-06	7.77e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HMGCS1—obesity	8.88e-06	7.74e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3R1—obesity	8.77e-06	7.64e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PNPLA2—obesity	8.62e-06	7.51e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLIN1—obesity	8.62e-06	7.51e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ACADM—obesity	8.62e-06	7.51e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PFKFB3—obesity	8.62e-06	7.51e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ANGPTL4—obesity	8.62e-06	7.51e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SAT1—obesity	8.62e-06	7.51e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CD—obesity	8.58e-06	7.47e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—SERPINE1—obesity	8.48e-06	7.39e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3CA—obesity	8.47e-06	7.38e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2—obesity	8.44e-06	7.36e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYTB—obesity	8.39e-06	7.31e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ACACB—obesity	8.39e-06	7.31e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—OXCT1—obesity	8.39e-06	7.31e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNG—obesity	8.37e-06	7.29e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PRKCD—obesity	8.32e-06	7.25e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—TYK2—obesity	8.25e-06	7.19e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—RHOA—obesity	8.18e-06	7.13e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PNLIP—obesity	8.17e-06	7.12e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SRD5A1—obesity	8.17e-06	7.12e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HTR2A—obesity	8.14e-06	7.09e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CA—obesity	8.14e-06	7.09e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—C3—obesity	8.13e-06	7.08e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CA—obesity	8.1e-06	7.06e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS3—obesity	8.1e-06	7.05e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3R1—obesity	8.1e-06	7.05e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CB—obesity	8.1e-06	7.05e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—obesity	8.09e-06	7.05e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SDC3—obesity	7.98e-06	6.95e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MAPK8—obesity	7.87e-06	6.85e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP26B1—obesity	7.8e-06	6.79e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—STS—obesity	7.8e-06	6.79e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HK2—obesity	7.8e-06	6.79e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IRS2—obesity	7.73e-06	6.74e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AGT—obesity	7.73e-06	6.73e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARD—obesity	7.63e-06	6.65e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LEP—obesity	7.57e-06	6.59e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOE—obesity	7.57e-06	6.59e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—obesity	7.5e-06	6.54e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CAV1—obesity	7.5e-06	6.53e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOA1—obesity	7.48e-06	6.52e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CB—obesity	7.47e-06	6.51e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC27A1—obesity	7.47e-06	6.51e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL1B—obesity	7.46e-06	6.5e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—obesity	7.41e-06	6.45e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GLUL—obesity	7.33e-06	6.39e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—FABP4—obesity	7.33e-06	6.39e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ESR1—obesity	7.23e-06	6.29e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—STAT3—obesity	7.19e-06	6.27e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—obesity	7.17e-06	6.25e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PRKCB—obesity	7.14e-06	6.22e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—F2—obesity	7.14e-06	6.22e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—BAD—obesity	7.05e-06	6.14e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ECHS1—obesity	6.95e-06	6.05e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—UCP3—obesity	6.95e-06	6.05e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HSD11B1—obesity	6.95e-06	6.05e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—UCP2—obesity	6.95e-06	6.05e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT1—obesity	6.92e-06	6.03e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—MAPK8—obesity	6.84e-06	5.96e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ADH1B—obesity	6.84e-06	5.96e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CG—obesity	6.83e-06	5.95e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IRS1—obesity	6.75e-06	5.88e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GPAM—obesity	6.73e-06	5.86e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ACSL1—obesity	6.73e-06	5.86e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARGC1B—obesity	6.73e-06	5.86e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MYC—obesity	6.68e-06	5.82e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TGFB1—obesity	6.67e-06	5.81e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT1—obesity	6.65e-06	5.79e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT1—obesity	6.62e-06	5.77e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PCK1—obesity	6.53e-06	5.69e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HADH—obesity	6.53e-06	5.69e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—FADS1—obesity	6.53e-06	5.69e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—POMC—obesity	6.5e-06	5.66e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—INS—obesity	6.47e-06	5.63e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL2—obesity	6.36e-06	5.54e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ACP5—obesity	6.36e-06	5.54e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—STAT3—obesity	6.26e-06	5.45e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF1—obesity	6.25e-06	5.45e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT2—obesity	6.25e-06	5.44e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—G6PD—obesity	6.19e-06	5.4e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SREBF2—obesity	6.12e-06	5.33e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HK1—obesity	6.12e-06	5.33e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CD—obesity	6.01e-06	5.23e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SERPINE1—obesity	5.94e-06	5.17e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LPA—obesity	5.91e-06	5.15e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LPIN1—obesity	5.78e-06	5.04e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TYK2—obesity	5.78e-06	5.03e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—STAT3—obesity	5.78e-06	5.03e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RHOA—obesity	5.73e-06	4.99e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CA—obesity	5.67e-06	4.94e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3R1—obesity	5.67e-06	4.94e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOS3—obesity	5.67e-06	4.94e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOA5—obesity	5.66e-06	4.93e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC22A1—obesity	5.4e-06	4.71e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CLOCK—obesity	5.4e-06	4.71e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MYC—obesity	5.37e-06	4.68e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—TGFB1—obesity	5.35e-06	4.66e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SULT2A1—obesity	5.27e-06	4.59e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GLP1R—obesity	5.27e-06	4.59e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CB—obesity	5.23e-06	4.56e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—DPYD—obesity	5.18e-06	4.51e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—obesity	5.02e-06	4.38e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PRKAR2B—obesity	4.99e-06	4.34e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—DCN—obesity	4.95e-06	4.31e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CA—obesity	4.94e-06	4.3e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CPT1A—obesity	4.82e-06	4.2e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NAMPT—obesity	4.72e-06	4.11e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LIPC—obesity	4.69e-06	4.09e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GCK—obesity	4.69e-06	4.09e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOC3—obesity	4.66e-06	4.06e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT1—obesity	4.63e-06	4.04e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CA—obesity	4.56e-06	3.97e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—obesity	4.55e-06	3.96e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CETP—obesity	4.53e-06	3.94e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SDC1—obesity	4.48e-06	3.9e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MAPK8—obesity	4.42e-06	3.85e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKR1C3—obesity	4.41e-06	3.84e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—obesity	4.37e-06	3.81e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SCARB1—obesity	4.34e-06	3.78e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SREBF1—obesity	4.21e-06	3.67e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GOT2—obesity	4.1e-06	3.57e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT3—obesity	4.05e-06	3.52e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—obesity	4.03e-06	3.51e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT1—obesity	4.03e-06	3.51e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—FASN—obesity	4.01e-06	3.49e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—BCHE—obesity	3.99e-06	3.48e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP2E1—obesity	3.85e-06	3.35e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NQO1—obesity	3.81e-06	3.32e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MYC—obesity	3.76e-06	3.27e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFB1—obesity	3.75e-06	3.27e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT1—obesity	3.72e-06	3.24e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GCG—obesity	3.65e-06	3.18e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC2A4—obesity	3.65e-06	3.18e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYCS—obesity	3.6e-06	3.14e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GGT1—obesity	3.54e-06	3.08e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GOT1—obesity	3.54e-06	3.08e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NCOA1—obesity	3.48e-06	3.03e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—STK11—obesity	3.43e-06	2.99e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP19A1—obesity	3.43e-06	2.99e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CA—obesity	3.19e-06	2.78e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—COMT—obesity	3.19e-06	2.78e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GNB3—obesity	3.15e-06	2.74e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARGC1A—obesity	3.15e-06	2.74e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HMOX1—obesity	3.13e-06	2.73e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GNAS—obesity	3.06e-06	2.67e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOB—obesity	3e-06	2.61e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LPL—obesity	2.86e-06	2.5e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—obesity	2.83e-06	2.46e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GPX1—obesity	2.79e-06	2.43e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CD36—obesity	2.72e-06	2.37e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT1—obesity	2.61e-06	2.27e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTHFR—obesity	2.58e-06	2.25e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARA—obesity	2.53e-06	2.2e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AGT—obesity	2.45e-06	2.13e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOE—obesity	2.4e-06	2.09e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CAV1—obesity	2.38e-06	2.07e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOA1—obesity	2.37e-06	2.07e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CG—obesity	2.17e-06	1.89e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARG—obesity	2.09e-06	1.82e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—POMC—obesity	2.06e-06	1.8e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—INS—obesity	2.05e-06	1.79e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CD—obesity	1.9e-06	1.66e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALB—obesity	1.88e-06	1.64e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3R1—obesity	1.8e-06	1.57e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NOS3—obesity	1.8e-06	1.57e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CB—obesity	1.66e-06	1.45e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—obesity	1.65e-06	1.43e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CA—obesity	1.01e-06	8.82e-06	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKT1—obesity	8.27e-07	7.2e-06	CbGpPWpGaD
